EUCTR2005-004122-70-GB进行中（未招募）1 期
Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine. - Immunogenicity of Prevenar in Ataxia telangiectasia
Great Ormond Street Hospital0 个研究点目标入组 30 人开始时间: 2005年9月12日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Genetically confirmed diagnosis of AT
- •2.Patient/Parental informed consent obtained (and assent from appropriately aged children)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients <2 years old
- •2.Consent/ assent not given
- •3.Patient receiving immunoglobulin therapy (around 12% of patients)
研究者
相似试验
已完成
不适用
Inmunogenicity-PCV-Carriage-Venezuelan High Risk ChildreInfection Prophylaxis of Streptococcus pneumoniaeRPCEC00000150Servicio Autónomo Instituto de Biomedicina110
进行中（未招募）
不适用
Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantly18 years old or older volunteers with general good healthEUCTR2012-003484-22-FIHelsinki University Central Hospital600
进行中（未招募）
不适用
Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantlyEUCTR2012-003484-22-SEHelsinki University Central Hospital300
尚未招募
不适用
Efficacy of pneumococcal conjugate vaccine in preventing acquisition and carriage of pneumococcal vaccine serotypes in Tanzanian children with human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS)Pneumococcal diseaseHIV/AIDSPublic Health - EpidemiologyInfection - Studies of infection and infectious agentsACTRN12610000999033Prof Robert Booy216
进行中（未招募）
不适用
Immunogenicity of pneumococcal vaccination after prime boosting in HIV-Infected Adults: A Randomised Controlled TrialThe primary objectives of this study are to:1.Prospectively evaluate immunological response to vaccination with the 23-valent polysaccharide vaccine (PPV23) in HIV infected patients over a one year period.2.Evaluate whether a strategy combining a prime with the 13-valent conjugate pneumococcal vaccine (PCV) followed by a boost with the PPV23 would improve immunogenicity against Streptococcus Pneumoniae Polysaccharides (SPP) in HIV-infected patients.EUCTR2011-000260-99-IEDepartment of Genitourinary medicine and Infectious Diseases, St James's Hospital, Dublin 8150